August 18, 2023 11:21 AM EDT

Merck's Welireg meets co-primary endpoint in kidney cancer PhIII; Noveome raises half of planned $40M VC round

Paul Schloesser

Associate Editor

Tyler Patchen

News Reporter

Merck said Friday morning that its HIF-2α inhibitor Welireg met the co-primary endpoint of progression-free survival in a Phase III trial for patients with advanced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck's Welireg meets co-primary endpoint in kidney cancer PhIII; Noveome raises half of planned $40M VC round

Paul Schloesser

Associate Editor

Tyler Patchen

News Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Mer­ck­'s Welireg meets co-pri­ma­ry end­point in kid­ney can­cer PhI­II; Noveome rais­es half of planned $40M VC round

Associate Editor

News Reporter

Sign up to read this article for free.

Merck's Welireg meets co-primary endpoint in kidney cancer PhIII; Noveome raises half of planned $40M VC round